PDF factsheet
      Z

antithrombotics in venous thrombosis for secondary prevention - 2, clinical trials results

apixaban 2.5mg versus placebo
AMPLIFY EXT 2.5mg, 2013
apixaban (2.5 mg and 5 mg, twice daily)
versus
placebo
patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy
apixaban 5mg versus placebo
AMPLIFY EXT 5mg, 2013
apixaban (2.5 mg and 5 mg, twice daily)
versus
placebo
patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy
aspirin versus placebo
ASPIRE, 2012
aspirin, at a dose of 100 mg daily, for up to 4 years
versus
placebo
patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism
Follow-up duration: 37.2 months median
WARFASA, 2012
aspirin, 100 mg daily for 2 years
versus
placebo
patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment
dabigatran versus placebo
RESONATE, 2013
dabigatran at a dose of 150 mg twice daily
versus
placebo
dabigatran versus warfarin
REMEDY, 2013
dabigatran at a dose of 150 mg twice daily
versus
idraparinux versus placebo
Van Gogh, 2007
NCT00071279
once-weekly injections of 2.5 mg of idraparinux for 6 months without monitoring
versus
placebo
patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted double-blind
low-intensity warfarin versus placebo
PREVENT, 2003
low-intensity warfarin (target INR, 1.5 to 2.0)
versus
placebo
Patients with idiopathic venous thromboembolism who had received full-dose anticoagulationdouble-blind
Follow-up duration: 2.1 years mean
rivaroxaban 10mg versus aspirin
EINSTEIN CHOICE (10mg), 2017
NCT02064439
Rivaroxaban 10 mg once daily for 12 months
versus
ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation
rivaroxaban 20mg versus aspirin
EINSTEIN CHOICE (20mg), 2017
NCT02064439
Rivaroxaban 20 mg once daily for 12 months
versus
ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation
rivaroxaban 20mg versus placebo
EISNTEIN EXT, 2010
rivaroxaban alone (20 mg once daily)for an additional 6 or 12 months
versus
placebo
patients who had completed 6 to 12 months of treatment for venous thromboembolism
VKA versus control
AUREC FVII, 2009
continue VKA for additional 24 months
versus
discontinuation
patients with first spontaneous VTE and FVIII levels >230 IU/dl after 6 montsh of VKA
Follow-up duration: 37 months mean
DACUS (Siragusa), 2008
NCT00438230
anticoagulants for 9 additional months
versus
no treatment
with a first episode of deep vein thrombosis, treated with OAT for 3 months and with Residual vein thrombosis
DURAC II, 1997
anticoagulant therapy continued indefinitely
versus
six months of oral anticoagulant therapy
patients who had had a second episode of venous thromboembolism
Follow-up duration: 4 years
PROLONG (Palarati), 2006
NCT00264277
resume treatment
versus
discontinue treatment
patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months and with abnormal D-dimer testing 1 month after the discontinuation of anticoagulation
Follow-up duration: 1.4 years
WODIT DVT, 2001
continuation for nine additional months
versus
discontinuation
Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy
Follow-up duration: at least two years
WODIT PE, 2003
Extended oral anticoagulant therapy
versus
patients after a first episode of pulmonary embolismwho had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding
VKA versus placebo
PADIS-PE (Couturaud), 2015
NCT00740883
additional 18-month treatment with warfarin
versus
placebo
patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist double-blind
warfarin versus control
Vitotec, 2009
continuation of warfarin for another 6 months
versus
discontinuation of warfarin
patients with idiopathic DVT After 6 months of standard therapy (heparin/LMWH, warfarin with target INR 2-3) and persistent echogenic masses of over 20% of venous diameter
warfarin versus low intensity warfarin
ELATE, 2003
continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0
versus
target INR of 1.5 to 1.9 (low intensity)
patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism open-label
Follow-up duration: 2.4 years mean
warfarin versus placebo
LAFIT, 1999
warfarin for a further 24 months
versus
placebo
patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolismdouble-blind
Follow-up duration: 10 months
Levine, 1995
continue warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks
versus
placebo
Patients with venographically confirmed acute proximal DVT who had received four weeks of warfarin after initial heparin and whose four week IPG was normal
ximelagatran versus placebo
THRIVE 3, 2003
ximelagatran (24 mg)
versus
placebo
patients with venous thromboembolism who had undergone six months of anticoagulant therapy

  Options


in first

in second

  Filter